

**UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION**

**IN RE: ZANTAC (RANITIDINE) PRODUCTS
LIABILITY LITIGATION**

MDL No. 2924

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO –24)

On February 6, 2020, the Panel transferred 12 civil action(s) to the United States District Court for the Southern District of Florida for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See* F.Supp.3d (J.P.M.L. 2020). Since that time, 189 additional action(s) have been transferred to the Southern District of Florida. With the consent of that court, all such actions have been assigned to the Honorable Robin L. Rosenberg.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Southern District of Florida and assigned to Judge Rosenberg.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the Southern District of Florida for the reasons stated in the order of February 6, 2020, and, with the consent of that court, assigned to the Honorable Robin L. Rosenberg.


This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Southern District of Florida. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is
pending at this time, the
stay is lifted.


Jul 02, 2020

CLERK'S OFFICE
UNITED STATES
JUDICIAL PANEL ON
MULTIDISTRICT LITIGATION

FOR THE PANEL:



John W. Nichols
Clerk of the Panel



**IN RE: ZANTAC (RANITIDINE) PRODUCTS
LIABILITY LITIGATION**

MDL No. 2924

SCHEDULE CTO-24 – TAG-ALONG ACTIONS

<u>DIST</u>	<u>DIV.</u>	<u>C.A.NO.</u>	<u>CASE CAPTION</u>
CALIFORNIA NORTHERN			
CAN	3	20-03913	Dudley v. GlaxoSmithKline LLC et al
CAN	3	20-03914	Goetz v. GlaxoSmithKline, LLC et al
CAN	3	20-03921	Cash v. GlaxoSmithKline, LLC et al
CAN	3	20-03931	Brittner v. GlaxoSmithKline, LLC et al
CAN	3	20-03946	Ortega v. GlaxoSmithKline, LLC et al
CAN	3	20-03948	Campbell v. GlaxoSmithKline, LLC et al
CAN	3	20-03959	Flores v. GlaxoSmithKline, LLC et al
CAN	3	20-03961	Astruc v. GlaxoSmithKline, LLC et al
CAN	3	20-03963	Brodie v. GlaxoSmithKline, LLC et al
CAN	3	20-03969	Harbaugh v. GlaxoSmithKline, LLC et al
CAN	3	20-03970	Reynolds v. GlaxoSmithKline, LLC et al
CAN	3	20-03972	Gregory v. GlaxoSmithKline, LLC et al
CAN	3	20-03973	Williams v. GlaxoSmithKline, LLC et al
CAN	3	20-03974	Hernandez v. GlaxoSmithKline, LLC et al
CAN	3	20-03978	Geurin v. GlaxoSmithKline, LLC et al
CAN	3	20-03980	Carbajal v. GlaxoSmithKline, LLC et al
CAN	4	20-03918	John Russell v. GlaxoSmithKline, LLC et al
CAN	4	20-03924	Salvatore v. GlaxoSmithKline, LLC et al
CAN	4	20-03954	White v. GlaxoSmithKline LLC et al
CAN	4	20-03968	Gigliello v. GlaxoSmithKline, LLC et al